Circadian clock represents anticipatory mechanism, highly conserved in the evolution, and impacting critically on most of aspects of the physiology. Although the circadian profiles of thyroid releasing hormone (TRH), thyroid stimulating hormone (TSH), thyroxine (T4) and triiodothyronine (T3) in the circulation have been well described, few studies have tackled the mechanisms underlying circadian regulation of the HPT axis function. Of note, an increasing body of evidence suggests a strong link between cellular circadian cycle, DNA damage, apoptosis control, and cancerogenesis. The talk will summarize current knowledge on the complex regulation of thyroid gland gene expression and function by the circadian oscillator. Molecular makeup of the human thyroid oscillator, as well as potential link between thyroid malignant transformation and alterations in the clockwork, will be highlighted.
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Over the last half-century, imaging thyroid disease with radionuclides has developed from "functional imaging" where radioiodine was used to localise "thyroid function," into "molecular imaging" following discovery and cloning of the sodium-iodide symporter (NIS) in the 1990s. Throughout this development it has maintained its role as a mainstay of diagnosis in thyroid disease, while iodine-131 therapy has maintained its position in radionuclide therapy. The advent of clinical PET in the last twenty years has highlighted the limitations of conventional gamma camera and SPECT imaging compared to the improved resolution, sensitivity and quantification offered by PET. Thus a search began for positron emitting alternatives to the conventional gammaemitters iodine-131, iodine-123 and technetium-99 m-pertechnetate. This was partially satisfied iodine-124, but its long half-life (4 days) and consequent high radiation dose, low positron abundance, and less than ideal PET imaging characteristics, spurred further searching for tracers labeled with the "ideal" positron emitter, fluorine-18. This presentation describes our work the development of PET tracers including resulting from this search, including F-18-tetrafluoroborate, F-18-fluorosulfonate and others, from conception and synthesis to clinical evaluation. In The talk will cover controversies concerning thyroid function tests in pregnancy, iodine supplementation in pregnancy, management of thyroid nodules and thyroid cancer in pregnancy, screening for thyroid disease during pregnancy, and the role of the obstetrician in management of women with thyroid disease in pregnancy. Pregnancy has a profound impact on the thyroid gland and is associated with important physiological changes to thyroid function. In addition, thyroid dysfunction and other thyroid diseases may be present before, during and after pregnancy and taken together these conditions represent a significant health burden affecting women of reproductive age. There is continued controversy regarding the definitions of normal thyroid function in pregnancy and whether mild thyroid dysfunction warrants follow-up and treatment. Evidence regarding optimal management of thyroid diseases in pregnancy is rapidly accumulating and the results of carefully conducted randomised controlled trials are changing recommendations regarding optimal practice. The American Thyroid Association (ATA) has brought out new guidelines regarding the management of thyroid disorders in the peri-partum period in March 2017 and UK guidelines are currently in development as part of a joint venture between the British Thyroid Association and the Royal College of Obstetricians and Gynaecologists (RCOG). In line with current practice in most fields of medicine a multi-disciplinary approach with close liaison between endocrinologists, obstetricians and health care professionals often results in optimal outcomes for mother and baby. This symposium aims to highlight the most recent evidence regarding management of thyroid disorders in pregnancy from an endocrine perspective. Background Alemtuzumab (anti-CD52; ALTZ), an effective therapy for relapsing/ remitting multiple sclerosis (MS), causes panlymphopenia with subsequent lymphocyte repopulation; 30-40% of patients develop secondary humoral autoimmunity, mainly thyroidal. Anti-thyrotropin-receptor (TSHR) autoantibodies (TRAb) can stimulate (TSAb), block (TBAb) or not affect ("neutral") TSHR function, with TSAb causing hyperthyroid Graves' disease (GD), and TBAb hypothyroidism. Low-affinity neutral TRAb could pre-exist in MS patients, then undergo somatic hypermutation to become high-affinity TSAb/TBAb post-ALTZ, causing thyroid dysfunction. Methods Sera from MS patients (Welsh Neuroscience Research Tissue Bank), 11 developing post-ALTZ thyroid autoimmunity (TA; 10 GD, 1 hypothyroidism) and 14 not developing it (NO-TA), evaluated at different time-points: 1) pre-ALTZ, 2) post-ALTZ before disease onset (TA) or latest time post-ALTZ (NO-TA), 3) post-ALTZ during/after thyroid dysfunction onset (TA only). Flow cytometry (FC) detected any TSHR-binding TRAb. Luciferase bioassays (LB) detected both TRAb presence and bioactivity (neutral/TSAb/ TBAb), also deduced from the corresponding thyroid function. TRAb positivity (TRAb+) was defined as FC and/or LB positivity. Results At time-point 1, 3/11 (27.3%) TA and 0/14 (0%) NO-TA patients were TRAb + (p = 0.07). At time-point 2, 5/11 (45.5%) TA and 4/14 (28.6%) NO-TA were TRAb + (p = 0.43). Among all TRAb + cases, TBAb were 2/7 (28.6%) in GD, 1/1 (100%) in hypothyroidism, and 3/4 (75%) in NO-TA. Conclusions A) Patients who developed TA tended to be TRAb + prior to ALTZ. Thus TRAb could provide a predictive marker of future TA. B) TRAb + patients were euthyroid at time-points 1-2, suggesting low-affinity antibodies unable to affect thyroid function. C) Post-ALTZ TBAb subtype is common. Methods 143 patients received outpatient radioiodine therapy for hyperthyroidism (1.4.2014-31.3.2015) of which 130 patients received treatment at their first clinic visit. Thirteen patients did not receive treatment for various reasons including failure to discontinue Carbimazole therapy, problems arranging appropriate family support or wish to further consider treatment options. Patients who underwent FNAC were sent a questionnaire to evaluate their experience. Results Following discussion in clinic, 130 patients received radioiodine therapy at their first visit Fifty-three of the 82 patients who underwent FNAC replied to the questionnaire and all were pleased to be investigated at their initial clinic visit. All but two were pleased to receive the result on the day. Conclusion A "one-stop thyroid service" reduces the need for unnecessary clinic visits, reduces travel time, time off work and inconvenience for patients and relatives, and reduces patients' anxiety following cytological investigation. Background By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer and has been hypothesised as a viable treatment for breast cancer. However, up to a quarter of patients are unable to accumulate sufficient radioiodide for effective treatment due to decreased expression of NIS and/or reduced plasma membrane localisation. Currently, the regulation of NIS trafficking and its localisation at the plasma membrane is ill-defined. Methods To identify novel NIS-interactors, and unravel the mechanism of NIS trafficking, mass spectrometry analysis was performed on proteins co-immunoprecipitating with lentivirally expressed NIS in cell plasma membrane extracts. To determine the biological impact of these putative interactors on NIS, siRNA knockdown of the top shortlisted interactors was followed by radioiodide uptake assays. Further, to validate interactors that altered NIS function, co-immunoprecipitation and proximity ligation assays were completed. Results NIS activity was significantly altered by ADP-ribosylation factor 4 (ARF4) and valosin containing protein (VCP) in thyroid and breast cancer cell lines stably-expressing NIS. ARF4 downregulation significantly decreased radioiodide uptake by 75% and 44%, and VCP downregulation increased radioiodide uptake by 71% and 56%, in the thyroid and breast cell lines, respectively. In contrast, ARF4 overexpression significantly increased radioiodide uptake by 89% and 43%, and VCP overexpression decreased radioiodide uptake by 52% and 38%, in thyroid and breast cell lines, respectively. Through both co-immunoprecipitation and proximity ligation assays it was confirmed that NIS interacts with ARF4 and VCP. Analysis of TCGA data from N = 58 matched papillary thyroid cancers revealed ARF4 is significantly repressed and VCP highly upregulated in thyroid cancer, providing a new putative explanation for repressed NIS function. Conclusion These studies elucidating the regulation of NIS localisation have identified two novel potential therapeutic targets for enhancing radioiodide uptake in patients who are radioiodide-refractory. Background Thyroid hormones are essential for skeletal development and adult bone maintenance, and exert their actions in the skeleton via thyroid hormone receptor α (TRα). Patients with mutations of the THRA gene encoding TRα have growth retardation, skeletal dysplasia, constipation and variable cognitive abnormalities. These features are consistent with impaired thyroid hormone action in TRα target tissues, most notably the skeleton. Mutant TRα proteins have impaired T3 binding but increased affinity for interaction with the nuclear receptor co-repressor (NCoR). NCoR recruits histone deacetylases to DNA promoter regions, and its interaction with TRα results in repression of T3 target gene expression. The phenotype in patients with THRA mutations is therefore thought to result from enhanced repression of the basal activity of T3 target genes in TRα sensitive tissues such as the skeleton. We hypothesised, therefore that (i) inactivation of NCoR or (ii) treatment with a histone deacetylase inhibitor (suberoylanilide hydroxamic acid, SAHA) would ameliorate the phenotype in a TRα mutant mouse disease model. Methods To investigate this hypothesis, we analysed skeletal phenotypes of: (i) Thra1 +/+ (wild-type), (ii) Ncor1 ΔID/ΔID (mutation in NCoR that prevents its interaction with TRα), (iii) Thra1 PV/+ (a severe dominant-negative mutation of TRα that cannot bind T3), and (iv) Thra1 PV/+ Ncor1
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(double mutant in which mutant NCoR does not interact with dominant-negative TRα). Adult mice were analysed following treatment with vehicle or SAHA (50 mg/kg body weight) from the age of 6 weeks for 2 months. The skeletal consequences of SAHA treatment were determined by x-ray microradiography, micro-CT scanning and biomechanical testing. Results Prevention of the interaction between dominant-negative mutation of TRα and NCoR ameliorated the skeletal dysplasia in Thra1 PV/+ mice, whereas treatment with the histone deacetylase inhibitor, SAHA, had no significant effect on linear growth, bone mineral content, cortical and trabecular bone structural parameters or bone strength. Conclusion These data suggest treatment with SAHA is unlikely to provide therapeutic benefit in individuals with severe THRA mutations. However, other compounds that target NCoR-TR interaction or its downstream actions may have therapeutic potential especially in individuals with milder THRA mutations. 
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Background
Reduced eyelid protrusion has been reported as a side-effect of prostaglandin analogue eye drops (Bimatoprost) in glaucoma treatment. The objective of this study is to determine if bimatoprost is effective at reducing proptosis in inactive thyroid eye disease (TED).
Methods
Following informed consent participants were randomised to receive bimatoprost or placebo for three months after which they underwent a two-month washout, before switching to the opposite treatment.
The primary outcome was to compare the change in exophthalmometry readings over the two 3-month treatment periods. This was supported by photographic assessments. Allowing 15% dropout rate, 31 patients were randomised in order to identify a treatment effect of 1.6 mm (p = 0.05, two-sided, power 0.88).
Results
There was female preponderance with 5:1 ratio and mean age of 55 (range 28-74). The median duration of TED was 7.6 (IQR 3.6-12.3) years. The majority were still suffering from diplopia (61.3%) with bilateral involvement (61.3%). Using multilevel modelling adjusted for baseline, phase and carryover, Bimatoprost resulted in -0.17 mm exophthalmometry change (95% CI -0.67 to +0.32) p = 0.490. Subgroup analysis on monocular disease did not show any benefit.
Conclusions:
Bimatoprost treatment over 3 months does not result in clinically meaningful improvement in proptosis. Over 60% of TED patients have diplopia, confirming the unmet clinical need in this patient group.
Background
The thyroid's ability to accumulate iodide via the sodium-iodide symporter (NIS) is utilised to successfully treat most thyroid cancers with radioiodide. However, approximately 25% of thyroid cancers lose functional NIS expression and become unresponsive to radioiodide therapy, resulting in a poorer prognosis. Our knowledge of NIS regulation is limited, but as dimerisation of NIS has been proposed, we sought to investigate NIS dimerisation and function. Methods A homology model of NIS structure was built based on the bacterial protein vSGLT using the modeling platform Phyre2, to identify residues potentially involved in dimerisation, which were mutated via site-directed mutagenesis. Proximity ligation assays (PLA) were used to assess dimerisation of wild-type and mutant NIS. Novel constructs conjugated to fluorescent proteins (cerulean or citrine) were created to further assess dimerisation using Fӧrster resonance energy transfer (FRET). Results Dimerisation of wild-type NIS was confirmed via PLA in both a thyroid (SW1736) and non-thyroid (HeLa) cell line. Furthermore, FRET increased in the presence of both fluorophore-conjugated NIS constructs compared to single expression (1.52 ± 0.10 vs 1.08 ± 0.18, P < 0.0001), validating dimerisation. We mutated five residues identified from our homology model (D237A, Y242A, T243A, Q471A and A525F), and two putative dimerisation motifs identified in the literature (glycine-and leucine-zipper motifs). PLA suggested that all mutants retained the ability to dimerise, indicating that dimerisation involves multiple or as yet undiscovered residues. Conclusion NIS dimerisation has been conclusively demonstrated using two discrete methodologies. Further work is ongoing to determine the critical residues, cellular localisation and regulation of NIS dimerisation and its impact on function. In contrast higher median TSH levels were found in the Autumn-Winter than in the Spring-Summer months [1.9 ± 0.73 vs. 1.8 ± 0.66 mu/l; 0.10]. An inverse relationship was present between 25(OH)D3 levels and serum TSH (r = -0.023; p < 0.00001) even after adjustment for age and sex. Regardless of season, higher TSH levels were found in patients with vitamin D insufficiency or deficiency in comparison to patients with optimal vitamin D levels.
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Conclusion
Our study confirms that seasonal variability exists for 25(OH)D3 and TSH secretion in euthyroid subjects. An inverse relationship exists between vitamin D status and serum TSH levels. The clinical relevance of this interaction requires further study especially with regards to the potential benefits of vitamin D replacement in restoring TSH levels in patients with subclinical or borderline hypothyroid states.
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Auditing the effectiveness of a joint thyroid eye clinic Shivani Gulati 1 , Nicola N Zammitt 2 1 College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; 2 Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary Edinburgh, Edinburgh, UK Correspondence: Shivani Gulati (shivani.gulati@hotmail.co.uk) Thyroid Research 2017, 10(Suppl 2):P4 Background EUGOGO recommends that patients with thyroid eye disease (TED) be managed in joint endocrinology/ophthalmology clinics but there is limited evidence for their efficacy. In May 2010, a multidisciplinary clinic was established in Edinburgh (originally monthly; now running weekly). Methods Clinic data from 01/08/2012-01/08/2016 was audited and compared to pre-clinic data (2009). Associated resources included leaflets on selenium, smoking and immunosuppression. Results 269 TED patients were seen over four years (median [range] age 51 years, male-to-female ratio 1:3.8). Time from referral to first appointment improved as the clinic became better established. Overall, 24 (29%) urgent referrals were seen within 14 days and 53 (52%) routine referrals were seen within 60 days. By the final year, 47% of urgent referrals and 71% of routine referrals were seen within 14 and 60 days respectively. Smoking status and selenium uptake were recorded for all patients. Of the 82 (30%) smokers, 18 (22%) successfully quit compared to a 6% quit rate in 2009. 71 (26%) patients had active disease (Clinical Activity Score (CAS) ≥ 3). Glucocorticoid treatment was considered in all cases with 46 (75%) receiving IV methylprednisolone (median CAS pre-treatment 4; post-treatment 2). 17 patients with active disease were not given steroids. 7 out of 8 patients who had short-course oral steroids reported a reduction in CAS so did not need IV treatment. 5 patients received rituximab. Conclusions Referral times, smoking cessation, selenium uptake and treatment of active disease have improved within the joint clinic, although there is still room for improvement. 
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Background
The cost of liothyronine (T3) has significantly increased, possibly affecting prescription practices. Methods An online questionnaire was designed to assess current T3 use by UK endocrinologists and to determine whether the price increase resulted in a change in primary care prescription practices. Consultant grade members of the Society for Endocrinology Thyroid Network were invited to partake.
Results
Results were analysed from 50 consultant respondents; the majority (85%) were aware of the recent price increase in T3 and had received queries from GPs reluctant to prescribe T3 in the past month (82%); 73% had received patient queries. While most trusts (63%) had no restrictions in place for T3 prescription, almost half (44%) of CCGs provided guidance regarding restriction of T3 use to GPs. The majority (82%) found the BTA guidance on T3 use helpful, with most (61%) welcoming further advice. T3 was prescribed by the majority (73%) of respondents, but very infrequently (84%; <1 patient/month) and mostly due to patient request. Respondents indicated that very few (<5%) patients attending clinic were treated with T3 alone (98%). Only 9% used thyroid extract. Most respondents (57%) are equally likely to use T3 compared with 2 years ago. Conclusions T3 is used by the majority of UK consultant endocrinologists to treat hypothyroidism, but very infrequently. Price changes in T3 have raised GP reluctance to prescribe T3, resulting in increased secondary care involvement. Current guidance from the BTA regarding T3 use is well regarded, but further advice given the price changes would be welcomed.
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Can an electronic protocol improve thyroid hormone replacement in general practice? Background Thyroid hormone replacement is frequently suboptimal but interventions that are proven to optimise therapy are lacking. We developed an electronic Protocol for Monitoring Patients on Thyroxine in General Practice (e-Prompt GP), an electronic alert system designed to prompt general practitioners to test and address out of range thyroid function tests in patients with hypothyroidism. Methods In this feasibility audit e-Prompt GP was installed in two general practices in Surrey, total population, 21,177, comprising 650 patients (3.1%) with hypothyroidism. Audits were undertaken at baseline and at 12 months (practice 1) and 3 months (practice 2) after installation. At each time point we determined the percentage of patients with hypothyroidism who had: (1) a thyroid function test in the preceding 12 months and (2) TSH concentration within the laboratory reference range of 0.35-5.0 mU/L. Results The proportion of patients who had had a thyroid test in 12 months increased from 89 to 93% in practice 1, and from 86 to 90% in practice 2. Likewise, the proportion of patients with reference range TSH improved from 66% to 74% in practice 1 and from 66 to 72% in practice 2. Conclusion An electronic protocol resulted in small improvements in the adequacy of thyroid hormone therapy in two general practices in this preliminary study. Controlled studies are needed to clarify the significance, applicability, and potential clinical relevance of this protocol in a wider variety of UK general practices.
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Use of alternative thyroid hormone replacement medication in a specialist clinic-an audit of compliance with national guidelines Flora Jane Cecil, Vinay Eligar, Colin M. Dayan Thyroid research group, Cardiff University School of Medicine, Cardiff, UK Correspondence: Flora Jane Cecil (CecilF@cardiff.ac.uk) Thyroid Research 2017, 10(Suppl 2):P7 Background Hypothyroidism describes the clinical syndrome in which there is a deficiency of circulating thyroid hormones. The prevalence of spontaneous hypothyroidism in the UK is 1-2%. Primary hypothyroidism is managed primarily with levothyroxine (L-T4), this is highly effective and safe however there is a subgroup of patients who are dissatisfied with this treatment and are interested in other ways to correct their thyroid function. Method This service evaluation reviewed the use of alternative thyroid hormone replacement in a specialist thyroid clinic to determine whether it is consistent with the National Guidelines. The results were obtained by assessing each patient's clinic notes and identifying whether the use of alternative thyroid replacement therapy matched the guidelines set by the British Thyroid Association (BTA). Each case was scored as compliant, partially compliant or non-compliant. Results In total there were 58 patients (Female to male ratio, 57:1) in the cohort. The average age was 50.5 years. Of these patients 58% had been diagnosed with autoimmune hypothyroidism, 14% with subclinical hypothyroidism, 7% Post radioiodine hypothyroidism, 7% with post-thyroidectomy hypothyroidism and 14% of which diagnosis was uncertain. With those on treatment, thyroid stimulating hormone (TSH) was suppressed in 69%. A total of 44 (75%) of patients were on liothyronine (L-T3) or Natural Desiccated Extract (NDT) and 84% of them benefitted from this treatment. In the evaluation, 32 cases scored compliant, 21 partially compliant, 3 non-compliant and 2 cases were unavailable to be commented on. Conclusion Managing patients in a tertiary specialist thyroid hormone replacement clinic is effective in ensuring that National Guidelines are followed for these patients. Further studies are required to determine if this approach reduces their exposure to the risks of over-replacement.
Background
Graves' disease and benign multinodular goitre are the common conditions requiring thyroidectomy in selected patient group as part of definitive management plan. Thyroid hormone replacement following total thyroidectomy is usually based upon the body weight (1.6μgm/Kg/day). A euthyroid state is maintained by monitoring serum TSH levels and adjusting the LT4 dose accordingly. Inadequate replacement with LT4 can be associated with persistent hypothyroid symptoms and if overreplaced, it can increase the risks of atrial fibrillation and osteoporosis. Methods We conducted a retrospective analysis of 138 patients who underwent total thyroidectomy, subdividing them into 2 groups, Graves' disease (n =54) and benign multinodular goiter (n = 84). Adequacy of thyroid hormone replacement was identified by TSH level at 4-6 week post operatively and at a 12-month interval.
Results
The cohort included 111 women and 27 men with an average age of 50 years. Up to 50% of the cohort is sub-optimal in achieving biochemical euthyroid state. Older individuals were less likely to be over-replaced in both groups. In the multinodular cohort females were more likely to be over-replaced than males OR = 3.92 (95%CI 0.82, 18.6) p = 0.08. Young females (age <40 years) were substantially more likely to be over replaced OR = 9.17 (95%CI 2.51, 33.4) p = 0.001. In contrast, females with Graves' disease cohort are likely to be under replaced in comparison to males (TSH > 4.5) OR = 0.24 (95%CI 0.07 0.41) p =0.007. We were unable to explain this unusual pattern between the two groups.
Conclusion
The current guidance to replace levothyroxine in post-thyroidectomy patients has not achieved euthyroid state in all as expected. Every 2nd patient fails to achieve target TSH levels. Almost 30% of young females have a suppressed TSH which can substantially increase their risk of atrial fibrillation and osteoporosis. Several factors including patient compliance and insufficient monitoring in the community may be driving this outcome.
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